Long-term predictive factors of the morphology based outcome in bare platinum coiled intracranial aneurysms: Evaluation by pre- and post-contrast 3D time-of-flight MR angiography

Purpose Our aim was to identify long-term predictive factors of the morphology-based outcome (MBO) of bare platinum coiled intracranial aneurysms. Materials and Methods A retrospective analysis of 96 bare platinum coiled intracranial aneurysms followed up from 1997 to 2016 using pre- and post-contrast 3D time-of-flight MR angiography (MRA) was performed. Logistic regression analysis was used to identify factors associated with a positive history of surrounding coil mass enhancement (SCME) and poor MBO. Spearman's rank correlation test was used to analyze the relationship between the initial angiographic result (IAR) class, sequential change of the SCME category, and MBO grade. Results Factors independently associated with poor MBO were incomplete IAR (OR=14.94, 95%CI: 2.46, 289.21, P=0.002) and a history of SCME (OR=4.13, 95% CI: 1.05, 18.65, P=0.043). The MBO grade strongly correlated with the IAR class (correlation coefficient [r]=0.84, P<0.0001). MBO grade correlated with sequential change of the SCME category (r=0.56, P<0.0001). The sequential change of the SCME category correlated with IAR class (r=0.53, P<0.0001). Conclusion Although IAR and its class were strong long-term predictive factors of MBO, a history of SCME and upgrading of sequential change of SCME category were also long-term predictive factors of the MBO of bare platinum coiled intracranial aneurysms

Hospital and clinic cooperation for the treatment of rheumatoid arthritis in Okayama Prefecture, Japan

Objective: To survey the current status and problems of cooperation between clinics and hospitals in Okayama Prefecture, Japan for the treatment of rheumatoid arthritis (RA). 　Methods: We distributed a questionnaire to 300 of the 983 Okayama Prefecture clinics that had either an internal medicine or orthopedic surgery department, from December 2013 to February 2014. The questionnaire covered practice pattern for RA treatment in clinics, current status of the hospital and clinic cooperation, and acceptance of the biologic therapy. 　Results: One hundred clinics responded to the questionnaire. Seventy percent of the clinics reported making referrals to rheumatologists before the initiation of RA treatment, and half of the other 30% of the clinics administered methotrexate as the first-line treatment for RA by their own decision. Sixty-six clinics cooperated with flagship hospitals, conducting medical and laboratory examinations, providing prescriptions, and treating common diseases of patients. These clinics expected the cooperating rheumatologists to follow-up patients every 3 to 6 months and to make the diagnosis, make decisions regarding RA treatment changes, and perform surgery. Seventy-one percent of the clinics responded that cooperation with a hospital is possible even for patients who are administered biologics. As reasons for no cooperation with the flagship hospitals, clinics noted the lack of information about rheumatologists in the area and recent trends in the management of RA. 　Conclusion: The current study reported, for the first time, the actual conditions of management of RA in clinics, as well as future problems of hospital and clinic cooperation in Okayama Prefecture

Robust antibody response after the third mRNA coronavirus vaccination in Japanese hemodialysis patients

Abstract Background Hemodialysis patients have chronic kidney disease, are often elderly, and have many complications such as hypertension, type 2 diabetes, cardiac disease, and cerebrovascular disease. Therefore, hemodialysis patients infected with COVID-19 are prone to severe disease. Vaccination is the most promising means of preventing the onset and reducing the severity of COVID-19. However, many reports have found that anti-spike antibody titers after two doses of mRNA vaccine are lower in hemodialysis patients than in healthy controls. For this reason, a third vaccination is recommended for hemodialysis patients. In Japan, there are several reports of a third vaccination, especially for hemodialysis patients. In this study, we also examined the antibody response to COVID-19 vaccine in Japanese hemodialysis patients who received the third dose of the vaccine. Methods Study participants received a third vaccination (257 with BNT162b2 vaccine and 5 with mRNA-1273 vaccine) approximately 7–9 months after the second (BNT162b2 vaccine). Anti-SARS-CoV-2 spike IgG antibody titers were measured (Abbott SARS-CoV-2 IgG II Quan) in 185 hemodialysis patients and 109 healthcare workers approximately 2 weeks after the second vaccination and in 162 hemodialysis patients and 100 healthcare workers approximately 2 weeks after the third. Results Following the second vaccination, 97.6% of the hemodialysis group and 100% of the control group were positive for the anti-spike antibody. The median level of the anti-spike antibody was 2728.7 AU/mL (IQR, 1024.2–7688.2 AU/mL) in the hemodialysis group and 10,500 AU/ml (IQR, 9346.1–2,4500 AU/mL) in the controls. Following the third vaccination, 99.4% of the hemodialysis group (only one person tested negative for the antibody) and 100% of the control group were positive for the anti-spike antibody. The median level of the anti-spike antibody was 20,000 AU/mL (IQR, 7729–37,000 AU/mL) in the hemodialysis group and 21,500 AU/ml (IQR, 14,000–32,250 AU/mL) in the control group. The factors involved in the low response to the BNT152b2 vaccine after the second vaccination included old age, low BMI, low Cr index, low nPCR, low GNRI, low lymphocyte count, steroid administration, and complications related to blood disorders. However, in hemodialysis patients, the response after the third vaccination was excellent, and all factors associated with the suppressed response to these vaccines were no longer significant. Conclusions The humoral response of hemodialysis patients to two doses of mRNA vaccine was weaker than that of healthy controls. However, a third vaccination eliminated that difference

SALON: Simplified Sensing System for Activity of Daily Living in Ordinary Home

As aging populations continue to grow, primarily in developed countries, there are increasing demands for the system that monitors the activities of elderly people while continuing to allow them to pursue their individual, healthy, and independent lifestyles. Therefore, it is required to develop the activity of daily living (ADL) sensing systems that are based on high-performance sensors and information technologies. However, most of the systems that have been proposed to date have only been investigated and/or evaluated in experimental environments. When considering the spread of such systems to typical homes inhabited by elderly people, it is clear that such sensing systems will need to meet the following five requirements: (1) be inexpensive; (2) provide robustness; (3) protect privacy; (4) be maintenance-free; and, (5) work with a simple user interface. In this paper, we propose a novel senior-friendly ADL sensing system that can fulfill these requirements. More specifically, we achieve an easy collection of ADL data from elderly people while using a proposed system that consists of a small number of inexpensive energy harvesting sensors and simple annotation buttons, without the need for privacy-invasive cameras or microphones. In order to evaluate the practicality of our proposed system, we installed it in ten typical homes with elderly residents and collected the ADL data over a two-month period. We then visualized the collected data and performed activity recognition using a long short-term memory (LSTM) model. From the collected results, we confirmed that our proposed system, which is inexpensive and non-invasive, can correctly collect resident ADL data and could recognize activities from the collected data with a high recall rate of 72.3% on average. This result shows a high potential of our proposed system for application to services for elderly people

Exacerbation of Elastase-Induced Emphysema via Increased Oxidative Stress in Metallothionein-Knockout Mice

Although the pathogenesis of chronic obstructive pulmonary disease (COPD) is not yet fully understood, recent studies suggest that the disruption of the intracellular balance of oxidative (such as reactive oxygen species (ROS)) and antioxidant molecules plays an important role in COPD development and progression. Metallothionein is an endogenous metal-binding protein with reported ROS scavenging activity. Although there have been many publications on the protective effects of metallothionein in the kidney and liver, its role in COPD models such as elastase- or cigarette smoke (CS)-induced lung injury is unknown. Thus, in the present study, we analyzed the elastase-induced lung injury model using metallothionein-knockout (MT-KO; MT-1 and -2 gene deletion) mice. The expression of MT-1 and MT-2 in the lungs of MT-KO mice was markedly lower compared with that in the lungs of wildtype (WT) mice. Porcine pancreatic elastase (PPE)-induced lung injury (alveolar enlargement and respiratory impairment) was significantly exacerbated in MT-KO mice compared with WT mice. Additionally, PPE-induced increases in the number of inflammatory cells, inflammatory cytokines, and cell death in lung tissue were significantly more pronounced in MT-KO mice compared with WT mice. Finally, using an in vivo imaging system, we also found that PPE-induced ROS production in the lungs was enhanced in MT-KO mice compared with WT mice. These results suggest that metallothionein may act as an inhibitor against elastase-induced lung injury by suppressing ROS production. These results suggest that metallothionein protein, or compounds that can induce metallothionein, could be useful in the treatment of COPD